PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32271680-0	2020	Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	56-67	coagulation factor II thrombin receptor	Homo sapiens	148-178	
33788669-2	2021	It was recently shown that FXa induces platelet aggregation via protease activated receptor 1 (PAR-1) which is in turn attenuated by rivaroxaban.	Rivaroxaban	133-144	coagulation factor II thrombin receptor	Homo sapiens	64-93	
33788669-2	2021	It was recently shown that FXa induces platelet aggregation via protease activated receptor 1 (PAR-1) which is in turn attenuated by rivaroxaban.	Rivaroxaban	133-144	coagulation factor II thrombin receptor	Homo sapiens	95-100	
32379576-0	2020	Letter by Violi et al Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	42-53	coagulation factor II thrombin receptor	Homo sapiens	134-164	
32379578-0	2020	Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	56-67	coagulation factor II thrombin receptor	Homo sapiens	148-178	
32271683-0	2020	Letter by Borst Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	36-47	coagulation factor II thrombin receptor	Homo sapiens	128-158	
28035779-9	2017	It is suggested that the relative downregulation of PAR-1 and PAR-2 by rivaroxaban compared with warfarin pretreatment might be partly involved in the mechanism of reduced hemorrhagic complications in patients receiving rivaroxaban in clinical trials.	Rivaroxaban	71-82	coagulation factor II thrombin receptor	Homo sapiens	52-57	
31859592-0	2020	Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.	Rivaroxaban	0-11	coagulation factor II thrombin receptor	Homo sapiens	92-121	
31859592-5	2020	METHODS AND RESULTS: In this study, we identified FXa as potent, direct agonist of the PAR-1 (protease-activated receptor 1), leading to platelet activation and thrombus formation, which can be inhibited by rivaroxaban.	Rivaroxaban	207-218	coagulation factor II thrombin receptor	Homo sapiens	87-92	
31859592-5	2020	METHODS AND RESULTS: In this study, we identified FXa as potent, direct agonist of the PAR-1 (protease-activated receptor 1), leading to platelet activation and thrombus formation, which can be inhibited by rivaroxaban.	Rivaroxaban	207-218	coagulation factor II thrombin receptor	Homo sapiens	94-123	
28035779-9	2017	It is suggested that the relative downregulation of PAR-1 and PAR-2 by rivaroxaban compared with warfarin pretreatment might be partly involved in the mechanism of reduced hemorrhagic complications in patients receiving rivaroxaban in clinical trials.	Rivaroxaban	220-231	coagulation factor II thrombin receptor	Homo sapiens	52-57